SG Americas Securities LLC Purchases New Shares in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

SG Americas Securities LLC purchased a new position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 13,566 shares of the company’s stock, valued at approximately $178,000.

A number of other hedge funds and other institutional investors have also modified their holdings of YMAB. Ameritas Investment Partners Inc. lifted its position in Y-mAbs Therapeutics by 39.9% in the first quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company’s stock valued at $60,000 after buying an additional 1,056 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Y-mAbs Therapeutics by 8.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 21,158 shares of the company’s stock worth $345,000 after acquiring an additional 1,657 shares in the last quarter. Massachusetts Financial Services Co. MA increased its position in shares of Y-mAbs Therapeutics by 3.5% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 82,202 shares of the company’s stock valued at $993,000 after purchasing an additional 2,760 shares during the last quarter. Rice Hall James & Associates LLC raised its stake in Y-mAbs Therapeutics by 4.2% in the second quarter. Rice Hall James & Associates LLC now owns 89,735 shares of the company’s stock valued at $1,084,000 after buying an additional 3,589 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in Y-mAbs Therapeutics by 8.0% during the second quarter. Bank of New York Mellon Corp now owns 120,954 shares of the company’s stock worth $1,461,000 after purchasing an additional 8,974 shares during the last quarter. 70.85% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Y-mAbs Therapeutics

In other news, insider Thomas Gad sold 30,000 shares of Y-mAbs Therapeutics stock in a transaction on Monday, September 16th. The stock was sold at an average price of $12.97, for a total value of $389,100.00. Following the completion of the sale, the insider now owns 67,681 shares of the company’s stock, valued at $877,822.57. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Y-mAbs Therapeutics news, insider Thomas Gad sold 30,000 shares of Y-mAbs Therapeutics stock in a transaction on Monday, September 16th. The shares were sold at an average price of $12.97, for a total value of $389,100.00. Following the transaction, the insider now owns 67,681 shares in the company, valued at $877,822.57. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Joris Wilms sold 5,000 shares of the company’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $14.69, for a total value of $73,450.00. Following the sale, the chief operating officer now owns 30,600 shares of the company’s stock, valued at $449,514. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 100,000 shares of company stock valued at $1,338,100. 21.50% of the stock is owned by insiders.

Analyst Ratings Changes

YMAB has been the subject of several research analyst reports. HC Wainwright restated a “buy” rating and issued a $22.00 target price on shares of Y-mAbs Therapeutics in a report on Tuesday, August 13th. Wedbush reaffirmed an “outperform” rating and issued a $23.00 target price on shares of Y-mAbs Therapeutics in a report on Tuesday, September 10th. Canaccord Genuity Group raised Y-mAbs Therapeutics to a “strong-buy” rating in a report on Tuesday, August 13th. BMO Capital Markets dropped their price objective on shares of Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 13th. Finally, Truist Financial initiated coverage on Y-mAbs Therapeutics in a research report on Friday, June 28th. They set a “buy” rating and a $21.00 target price on the stock. One investment analyst has rated the stock with a sell rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.14.

Y-mAbs Therapeutics Trading Up 0.1 %

YMAB stock opened at $14.87 on Thursday. Y-mAbs Therapeutics, Inc. has a 52 week low of $4.69 and a 52 week high of $20.90. The company has a market cap of $652.54 million, a P/E ratio of -30.35 and a beta of 0.70. The company’s 50-day moving average price is $13.82 and its 200 day moving average price is $13.14.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.08). The business had revenue of $22.80 million during the quarter, compared to analysts’ expectations of $23.09 million. Y-mAbs Therapeutics had a negative net margin of 28.44% and a negative return on equity of 24.88%. During the same period last year, the company earned ($0.14) EPS. On average, equities research analysts expect that Y-mAbs Therapeutics, Inc. will post -0.6 earnings per share for the current year.

Y-mAbs Therapeutics Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.